Evaluation of the systemic and therapeutic repercussions caused by drug interactions in oncology patients

• Main Authors: Camila Ribeiro de Arruda Monteiro, Jean Henri Maselli Schoueri, Debora Terra Cardial, Lívia de Castro Linhares, Karine Corcione Turke, Lia Vineyard Steuer, Levy Werneck de Almeida Menezes, Igor Luiz Argani, Claudia Sette, Daniel de Iracema Gomes Cubero, Auro del Giglio
• Format: Article
• Language: English
• Published: Associação Médica Brasileira
• Series: Revista da Associação Médica Brasileira
• Subjects: Interações medicamentosas; Antineoplásicos/efeitos adversos; Oncologia
• Online Access: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302019000500611&lng=en&tlng=en

SUMMARY INTRODUCTION: Drug interaction is an important cause of global morbidity. It is of particular importance in cancer patients since they are often in use of polypharmacy, related to interactions between the drugs and the chemotherapeutics used. OBJECTIVE: To evaluate the drug interaction between chemotherapy and other drugs in cancer patients. METHODS: a cross-sectional study carried out in the outpatient oncology department of a public tertiary hospital. Two hundred thirty-five patients were included, and the drugs they were using were identified. Using the MedScape and Epocrates database, we evaluated the interactions between medications and chemotherapy by defining their frequency and dividing their severity from interaction into mild, close monitoring necessity and severe. RESULTS: 161 patients had some drug interaction. We identified 9 types of mild interactions, 23 types of interactions with close monitoring necessity, and 2 types of serious interactions. The most frequent interactions were between fluorouracil and leucovorin (32 cases) and cyclophosphamide and doxorubicin (19 cases). Serious interactions were between aspirin and pemetrexed; and leucovorin and Bactrim. CONCLUSION: In the present study, drug interactions were frequent, including serious interactions with a potential increase in morbidity and mortality. Thus, it is necessary for oncologists to draw up a therapeutic plan considering potential interactions between prescribed chemotherapy and current medications in use by patients.